Piyasa açık· · EUR · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 29 September 2026 – 6 PM CET Disclosure of a transparency notification from BlackRock, Inc. Pursuant to the Belgian act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from BlackRock, Inc., dated 24 September 2026. Notification from BlackRock, Inc. On 25 September 2026, Fagron received a transparency notification from BlackRock, Inc. informing the Company
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 21 March 2026 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 43,920 new shares have been issued on 21 September 2026. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 507,764,714.08. The total number of shares with voting rights after the issue amounts
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 30 July 2026 – 7:00 AM CET Fagron delivers strong H1 2026 performance with 16% topline growth and reiterates FY 2026 guidance Fagron, the leading global player in pharmaceutical compounding today publishes its first half results for the period ending 30 June 2026. Key Highlights Revenue up 16.0% to €552.5 million (17.5% at CER), with organic growth of 3.1% at CER, led by EMEA and Latin America and supported by contributions fr
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.